Abstract
The unrivaled potential of T cells for targeted immune function is central to the eradication of cancer. While their natural anti-tumor response might sometimes be insufficient, several studies and importantly, multiple clinical trials in terminally-ill cancer patients have demonstrated that it is possible to design novel and efficient immunotherapeutic approaches based on the adoptive transfer of autologous tumor-specific T lymphocytes. Herein, we will expand on the development and the use of such strategies using tumor-infiltrating lymphocytes or genetically-engineered T cells. We will also comment on the requirements and potential hurdles encountered when elaborating and implementing such treatments as well as the exciting prospects for this kind of emerging personalized medicine therapy.
Original language | English |
---|---|
Title of host publication | Interaction of Immune and Cancer Cells |
Publisher | Springer-Verlag Wien |
Pages | 207-232 |
Number of pages | 26 |
ISBN (Electronic) | 9783709113004 |
ISBN (Print) | 3709112990, 9783709112991 |
DOIs | |
State | Published - 1 Jan 2014 |
All Science Journal Classification (ASJC) codes
- General Immunology and Microbiology
- General Medicine